Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Onconova Therapeutics, Inc. to Present at the Cowen and Company 34th Annual Health Care Conference

TRAW

NEWTOWN, Pa., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and CEO, will present at the Cowen and Company 34th Annual Health Care Conference in Boston, MA. The presentation will take place on Wednesday, March 5th at 11:20 a.m. ET.

A live webcast will be available at this link or can be accessed by visiting "Events & Presentations" in the Investors and Media section of the Company's website at www.onconova.com. An archived replay of the webcast will be available on the Company's website for 90 days after the conference.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are in clinical trials, and several candidates are in pre-clinical stages. For more information, please visit http://www.onconova.com

CONTACT: Onconova Therapeutics
         Benjamin Hoffman, 267-759-3680
         bhoffman@onconova.us
         
         Media:
         
         MacDougall Biomedical Communications
         Chris Erdman, 781-235-3060
         chris@macbiocom.com


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today